What Real-World Use Reveals About Long-Acting Therapy

As long-acting HIV therapies move into broader clinical use, real-world data are shedding light on an important practical question: how much flexibility exists around dosing schedules? Findings from the OPERA cohort suggest that cabotegravir plus rilpivirine (CAB+RPV LA) may be more “forgiving” than initially anticipated.
Although only about half of patients in the study received injections exactly on schedule, overall virologic outcomes remained strong. Many patients experienced short or even longer delays between injections, yet rates of viral suppression were largely maintained, and virologic failure remained rare. These results provide reassurance that strict adherence to injection timing, while still ideal, may not be as critical as once thought.
For clinicians, this flexibility could significantly reduce the logistical burden associated with administering long-acting therapy. In real-world settings, patients may miss appointments due to transportation issues, work conflicts, or other barriers. The ability to accommodate minor delays without compromising efficacy enhances the feasibility of implementing these regimens more widely.
At the same time, experts caution that these findings should be interpreted carefully. Controlled clinical trials emphasized strict adherence to dosing schedules, and deviations in practice should still be managed proactively. Additionally, questions remain about the limits of this “forgiveness” and how longer or repeated delays might impact resistance risk over time.
Nevertheless, these data highlight a key advantage of long-acting therapy: its potential to align more closely with real-world patient behavior, offering both efficacy and flexibility in the management of HIV.